A Study of LY3841136 in Overweight and Obese Participants

NCT06345066 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Tirzepatide
DRUG: LY3841136
DRUG: Placebo

Sponsor

Eli Lilly and Company